IP Library Granted Patent US 11,576,744
Granted Patent B2
US 11,576,744 · App. 17/703,238 · Granted Feb 14, 2023

Thermosensitive bio-adhesive hydrogel for removal of ureteral and renal stones

Inventors: Ralph V. Clayman (Irvine, CA); Pengbo Jiang (Irvine, CA); Mark Schoenberg (Pikesville, MD); Omer Tsipori (Sha'ar Efraim, IL)
Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; UROGEN PHARMA LTD.
A61B90/04A61B18/26A61K31/722A61L24/0031A61L24/08A61B17/22004A61B2017/22082A61B2090/049A61B2090/0472
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,576,744
App. No.
17/703,238
Granted
Feb 14, 2023
Kind
B2
Abstract

Provided herein are methods for treating nephrolithiasis and protecting the urothelium and inner lining of the kidney from thermal damage during lithotripsy by use of a thermosensitive bio-adhesive hydrogel. The described method dramatically improved the efficiency and effectiveness of stone clearance compared to conventional techniques while providing protection to the urothelium from potentially damaging temperature spikes.

Claims (35)

1. A method for treatment of a nephrolithiasis in a subject, the method comprising:

administering to the subject a thermo-reversible hydrogel into the subject's renal pelvis to encapsulate the nephrolithiasis; and

providing a lithotripsy procedure to the subject,

wherein stone clearance rate is at least 94%, and

wherein the thermo-reversible hydrogel comprises chitosan or at least one tri block copolymer having a general formula ABA or BAB copolymer, wherein A is a hydrophilic polymer block and B is a hydrophobic block polymer,

thereby treating the nephrolithiasis.

2. The method of claim 1 , wherein the thermosensitive thermo-reversible hydrogel protects urothelium of the subject from internal thermal damage or disruption resultant from the lithotripsy procedure.

3. The method of claim 2 , wherein the hydrogel partially or completely protects the urothelium from thermal damage.

4. The method of claim 3 , wherein the hydrogel inhibits peak intra-calyceal or intraureteral temperature of 38° C. during the lithotripsy procedure.

5. The method of claim 1 , wherein the stone clearance is at least 99%.

6. The method of claim 1 , wherein the method inhibits a renal backflow selected from the group consisting of pyelovenous, pyelosinus, and pyelolymphatic backflow.

7. The method of claim 1 , wherein the lithotripsy procedure comprises exposing the patient to a high-power laser capable of reaching 200-500 watts.

8. The method of claim 1 , wherein the lithotripsy is selected from the group consisting of ultrasonic lithotripsy, holmium laser lithotripsy (YAG), thulium fiber laser lithotripsy, super pulse thulium fiber laser lithotripsy, pneumatic, and electrohydraulic.

9. The method of claim 1 , wherein the tri block copolymer having an ABA formula is EPO/PPO/EPO block copolymer.

10. The method of claim 9 , wherein the tri block copolymer having an ABA formula has an average molecular weight 1100-20000 Da inclusive.

11. The method of claim 1 , wherein the tri block copolymer having ABA formula is Poloxamer 407 or Poloxamer 338.

12. The method of claim 1 , wherein the hydrogel composition further comprises a mucoadhesive polymer.

13. The method of claim 1 , wherein the hydrogel composition comprises 15% (w/w)— 40% (w/w) poloxamer 407 or Poloxamer 338 or any combination thereof, wherein the hydrogel further optionally includes 0.05% hydroxyl propylmethyl cellulose (HPMC).

14. The method of claim 1 , wherein the hydrogel encapsulates the nephrolithiasis.

15. The method of claim 1 , wherein the lithotripsy further comprises clearing stone fragments left in the hydrogel with a ureteroscope brush, sponge, suction, or other device exclusive of stone baskets or pre-existing graspers.

16. The method of claim 1 , wherein the hydrogel comprises about 27% or 30% Poloxamer 407.

17. The method of claim 1 , wherein the hydrogel comprises about 27% or 30% Poloxamer 338.

18. The method of claim 1 , wherein an intrarenal pressure does not rise above 40 cm H 2 O.

19. A method for protecting a subject from thermal damage or disruption during lithotripsy, the method comprising:

administering to the subject a thermosensitive bio-adhesive hydrogel; and

providing a lithotripsy procedure to the subject,

wherein the administration of the thermosensitive bio-adhesive hydrogel protects the subject from urothelium thermal damage associated with the lithotripsy, and

wherein the thermo-reversible hydrogel comprises chitosan or at least one tri block copolymer having a general formula ABA or BAB copolymer, wherein A is a hydrophilic polymer block and B is a hydrophobic block polymer,

thereby protecting the subject from thermal damage or disruption of the lithotripsy procedure.

20. A method for inhibition of nephrolithiasis regrowth in a subject, comprising:

administering to the subject a thermosensitive bio-adhesive hydrogel; and

providing a lithotripsy procedure to the subject,

wherein the administration of the thermosensitive bio-adhesive hydrogel encapsulates the renal stones and prevents displacement of renal stones during the lithotripsy procedure, and

wherein the thermo-reversible hydrogel comprises chitosan or at least one tri block copolymer having a general formula ABA or BAB copolymer, wherein A is a hydrophilic polymer block and B is a hydrophobic block polymer,

thereby inhibiting renal stone regrowth in a subject.

Assignments (7)
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 2, 2026
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 074994/0338 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Aug 18, 2025
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 072472/0233 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Mar 6, 2025
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 070434/0319 →
PATENT SECURITY AGREEMENT Recorded Mar 18, 2024
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC
Reel/Frame 066805/0346 →
PATENT SECURITY AGREEMENT Recorded Aug 18, 2023
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064641/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: TSIPORI, OMER; SCHOENBERG, MARK
To: UROGEN PHARMA LTD.
Reel/Frame 062278/0061 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: CLAYMAN, RALPH V.; JIANG, PENGBO
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 062278/0012 →
Continuity (2)
Provisional Application 63165744 · Mar 25, 2021
Related Publication 20220304766A1 · Sep 29, 2022